|Bid||283.77 x 800|
|Ask||288.30 x 1400|
|Day's range||282.00 - 285.78|
|52-week range||170.05 - 285.78|
|Beta (5Y monthly)||1.05|
|PE ratio (TTM)||10.55|
|Earnings date||29 July 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||29 Mar 1994|
|1y target est||305.92|
LabCorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
LabCorp's (LH) second-quarter base-business performance is expected to have registered a faster recovery rate compared to the first quarter.
Improvement in demand at non-COVID business and continued strength in Bio-Rad's (BIO) Life Science segment are likely to have contributed to Q2 results.